Catalog No.
Product Name
Application
Product Information
Citations
-
CXCR5 Inhibitor
YU241279 is a selective inhibitor of CXCR5, targeting the CXCL13-mediated signaling pathways. It effectively inhibits Gαq-dependent calcium influx and Gαi2-dependent cAMP reduction in CXCR5-expressing cells, leading to reduced proliferation of lymphoma cells. In preclinical studies, YU241279 demonstrated a significant reduction in tumor burden within the peripheral blood and bone marrow of mice with lymphoma. This compound is suitable for research into angioimmunoblastic T-cell lymphoma and Burkitt B-cell lymphoma. -
Dopamine Receptor Antagonist
N-(p-Aminophenethyl)spiperone is a selective antagonist of D2-like dopamine receptors. This compound binds specifically to the ligand recognition sites of functional D2 and D3 receptors, making it a valuable tool for researchers studying dopamine signaling pathways. N-(p-Aminophenethyl)spiperone is primarily used for labeling, localizing, and identifying D2 and D3 dopamine receptors in various biological systems. -
β2-adrenergic receptor Agonist
Methoxyfenoterol is a selective β2-adrenergic receptor agonist known for its ability to stimulate intracellular cAMP accumulation. It exhibits significant anti-proliferative effects on tumor cells by inducing G1 cell cycle arrest, upregulating p27, and downregulating cyclin D1 and cyclin A levels, while also inhibiting Akt phosphorylation. Additionally, Methoxyfenoterol is capable of crossing the blood-brain barrier, demonstrating efficacy in inhibiting the growth of astrocytoma xenografts. This compound is primarily utilized in research related to astrocytoma and glioblastoma. -
Antipsychotic Agent
Clopipazan is a potent antipsychotic agent that primarily targets dopamine receptors in the brain. Its primary mechanism of action involves modulating dopaminergic activity, which contributes to its therapeutic effects in the treatment of various psychiatric disorders, including schizophrenia. Clopipazan is utilized in research to explore neural pathways and potential therapeutic interventions for mental health conditions. -
Antihistamine Agent
Buclizine is an orally active antihistamine that targets histamine receptors, reducing allergic responses. In addition to its antiallergic properties, Buclizine has demonstrated teratogenic effects in rodent models and exhibits anti-tumor activity, making it of interest in cancer research. Its diverse mechanisms of action make it valuable for studies on histamine-related pathways and potential therapeutic applications in oncology. -
Adrenergic Receptor Antagonist
Tolazoline is an α-adrenergic receptor antagonist that plays a critical role in modulating vascular responses. It inhibits noradrenaline-induced cell contraction, affects vascular resistance, increases arterial pressure, and can reverse both bradycardia and tachypnea. This compound is valuable for studying erectile dysfunction, assessing α2-adrenergic receptor agonist-related poisoning, and investigating skin vascular diseases. -
alpha-adrenoceptor Antagonist
Acepromazine is a phenothiazine tranquilizer primarily acting as an alpha-adrenoceptor antagonist. It exhibits sedative and tranquilizing effects by blocking the adrenergic receptors, which can be valuable in veterinary medicine. Acepromazine is commonly utilized in studies involving sedation, anesthesia, and behavioral research, making it an important reagent for exploring neuropharmacological pathways. -
Antipsychotic Agent
Clomacran is a potent antipsychotic agent that primarily targets dopamine receptors in the brain, particularly the D2 receptor. It exhibits significant efficacy in alleviating symptoms associated with various psychotic disorders. This compound is widely utilized in preclinical research to investigate its neuropharmacological effects and potential therapeutic applications in the treatment of schizophrenia and other related conditions. -
Anti-adrenergic Agent, Anti-anginal Agent
L 8412 is a potent anti-adrenergic agent that primarily targets adrenergic receptors, leading to decreased heart rate and myocardial oxygen demand. It exhibits significant anti-anginal activity, making it valuable in cardiovascular research. This compound is utilized for studying the effects of adrenergic modulation on heart function and in the development of therapies for angina pectoris. -
Platelet Aggregation Inhibitor
Evategrel is a potent platelet aggregation inhibitor that primarily targets ADP receptors on platelets. This compound effectively reduces thrombus formation, making it useful for research in cardiovascular diseases and the study of clotting mechanisms. Its ability to modulate platelet activity supports investigations into antiplatelet therapies and their applications in preventing thrombotic events. -
Antihypertensive Agent
Alkaloids, Rauwolfia are derived from the root of Rauwolfia serpentina and act primarily as antihypertensive agents. These bioactive compounds have been shown to effectively lower blood pressure by targeting adrenergic receptors and modulating central nervous system activity. They are widely utilized in research to investigate hypertension and related cardiovascular conditions. -
Active Compound
Fluphenazine enanthate is a long-acting injectable antipsychotic compound that primarily targets dopamine receptors. It is utilized in the treatment of schizophrenia, providing sustained therapeutic effects that assist in managing acute and chronic symptoms of the disorder. Researchers can explore its pharmacological properties and effects on neurotransmitter dynamics in various experimental models related to psychosis and mental health disorders. -
Natural Extract
Yohimbe extract primarily targets adrenergic receptors due to its active component, yohimbine, an alkaloid. It is recognized for its biological activities, including the enhancement of sexual function, potential weight loss benefits, and promotion of blood circulation. This natural extract is widely utilized in pharmacological research and studies focused on cardiovascular health and metabolic regulation. -
Anti-Schizophrenia Agent
Zuclopenthixol decanoate is an antipsychotic compound that primarily targets dopamine receptors in the central nervous system. This long-acting formulation is utilized in research focused on schizophrenia and other serious mental health disorders, offering insights into therapeutic interventions and treatment protocols. Its sustained release properties allow for improved management of symptoms, making it valuable in preclinical and clinical studies. -
5-HT3 receptor antagonist
(R)-RS 56812 is a selective antagonist of the 5-HT3 receptor. This compound has been shown to enhance cognitive performance in primate models, particularly in tasks involving delayed matching. The (R) isomer exhibits greater efficacy in facilitating cognitive function compared to its (S) counterpart, suggesting potential therapeutic applications in conditions associated with cognitive decline. -
Platelet Aggregation Inhibitor
Prostaglandin I3 sodium is a potent inhibitor of platelet aggregation, primarily acting through the stimulation of adenylate cyclase, which increases cyclic AMP levels in platelets. This compound also exhibits vasodilatory properties, making it useful in studies related to cardiovascular health and thrombotic disorders. Its applications include research into the modulation of vascular tone and the prevention of platelet-related complications in various disease models. -
Natural Product
4-(cis)-Acetyl-3,6,8-trihydroxy-3-methyldihydronaphthalenone is a natural product derived from Senna siamea, primarily investigated for its interactions with adenosine receptors. Although it demonstrates very low affinity for the adenosine A1 receptor (Ki > 50 μM), its unique structural features may offer insights into the modulation of bioactive compounds in various biological systems. This compound can serve as a valuable tool in research exploring the pharmacological properties of natural products. -
Adrenergic Prodrug
Dibutepinephrine is an orally active adrenergic prodrug that targets adrenergic receptors. It demonstrates significant efficacy in rapidly alleviating allergic symptoms, making it a valuable tool for studying severe allergic reactions. This compound is useful in research focused on the mechanisms of allergic responses and the development of therapeutic interventions. -
CCK-AR Agonist
GW-5823 is a selective agonist of the cholecystokinin A receptor (CCK-AR), exhibiting an EC50 of 70 nM. This compound plays a crucial role in modulating appetite and satiety signals, making it valuable for research focused on obesity and metabolic disorders. Its specificity allows for detailed investigations into CCK-AR-related pathways and therapeutic potentials in weight management. -
Anti-Platelet Aggregation Agent
[Rh(cod)Cl]2 (Chloro(1,5-cyclooctadiene)rhodium(I) dimer) functions as an anti-platelet aggregation agent by inhibiting platelet-activating factor-mediated aggregation, with IC50 values of 5.2 μM in rabbit platelets and 43.3 μM in human platelet-rich plasma. It also inhibits thrombin-, ADP-, and collagen-induced aggregation, showing IC50 values of 16.7 μM, 162 μM, and 69.8 μM, respectively. This compound is valuable for research into cardiovascular diseases, particularly thrombosis. -
Ester Product
Arachidoyl ethanolamide is an ester derivative of arachidonic acid that functions primarily as a bioactive lipid mediator. It is known to modulate various physiological processes by interacting with cannabinoid receptors and has potential implications in pain modulation and inflammation. This compound is utilized in research to investigate endocannabinoid signaling pathways and their roles in various biological systems. -
LAI Antipsychotic
Aripiprazole Lauroxil is a long-acting injectable antipsychotic targeting dopamine receptors D2 and D4. It is an N-acyloxymethyl proagent of Aripiprazole, which undergoes enzymatic cleavage by esterases in the body to yield N-hydroxymethyl aripiprazole and lauric acid, further converting to aripiprazole and formaldehyde. This compound exhibits therapeutic activity in the management of schizophrenia and is utilized in research related to psychotropic medications and long-term treatment strategies. -
GLP-1R Agonist
GLP-1R Agonist 3 is a potent agonist of the glucagon-like peptide-1 receptor (GLP-1R). This compound, a modified imidazole derivative, plays a significant role in modulating insulin secretion and glucose homeostasis. GLP-1R Agonist 3 is primarily utilized in research focused on diabetes and metabolic disorders, offering avenues for developing novel therapeutic strategies. -
Antipsychotic Agent
Carphenazine is a phenothiazine antipsychotic agent that primarily targets dopamine receptors in the central nervous system. It exhibits significant antipsychotic activity, making it useful for studying the mechanisms underlying chronic schizophrenic psychoses. This compound is employed in research to better understand therapeutic interventions for various psychotic disorders. -
Platelet Aggregation Inhibitor
Cloricromen hydrochloride is a potent platelet aggregation inhibitor that effectively targets and modulates platelet activation pathways. This compound has demonstrated the ability to inhibit platelet aggregation in both human and experimental thrombosis models, making it a valuable reagent for research into cardiovascular diseases and thrombotic disorders. Cloricromen hydrochloride is suitable for studies focused on the mechanisms of platelet function and the development of antithrombotic therapies. -
CGRP Antagonist
SB 268262 is a selective antagonist of the calcitonin gene-related peptide (CGRP) receptor. This compound exhibits high affinity for CGRP receptors in the human brain, making it a valuable tool for studying CGRP signaling pathways. SB 268262 is applicable in research investigating the pharmacological properties of non-peptide CGRP receptor antagonists, also known as gepants, in models including rat, pig, and human meninges. -
Platelet Aggregation Inhibitor
KP-10614 is a potent, orally active inhibitor of platelet aggregation, primarily targeting ADP-induced aggregation with an IC50 of 1 nM. This compound exhibits dose-dependent inhibition of ex vivo platelet aggregation in rat models. KP-10614 demonstrates significant antithrombotic effects across various thrombosis models, making it a valuable tool for research into thrombotic diseases.
